Literature DB >> 15041159

Influence of HLA-DRB1 alleles on lymphoproliferative responses to a naturally processed and presented measles virus phosphoprotein in measles immunized individuals.

Inna G Ovsyannikova1, Gregory A Poland, Nathan J Easler, Robert A Vierkant.   

Abstract

Identification of stimulatory T-cell epitopes recognized by CD4+ T lymphocytes is important for vaccine development. Our previous studies using mass spectrometry identified a naturally processed HLA class II restricted DRB1*0301 T cell epitope in the measles virus phosphoprotein, MV-P1 (residues 179-197). Here we provide lymphocyte proliferation data from peripheral blood mononuclear cells (PBMC) obtained from 131 HLA-DRB1*0301-positive and HLA-DRB1*0301-negative (HLA discordant) individuals previously immunized against measles and report that a single amino acid substitution in the MV-P1 T cell epitope can reduce T cell proliferation and CD4+ T-cell recognition. Measles virus and measles peptide-specific lymphoproliferative responses and HLA-DRB1 allele associations reveal that the DRB1*0701 allele provided suggestive evidence of association with both measles virus (p = 0.03) and MV-P1 peptide (p = 0.06) lymphoproliferation. A marginally significant increase in the frequency of the *0301 allele (p = 0.10) was found among subjects who demonstrated low cellular responses to the measles virus. We found no associations between proliferation levels to the MV-P1 and MV-P2 peptides with *0301 alleles. We speculate that the glutamic acid at position 192 of the measles phosphoprotein is a critical immunogenicity factor and may influence the antigenicity of the naturally processed HLA class II MV-P1 epitope.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041159      PMCID: PMC1853292          DOI: 10.1016/j.humimm.2003.12.002

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  32 in total

Review 1.  Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes.

Authors:  G A Poland
Journal:  Vaccine       Date:  1999-03-26       Impact factor: 3.641

2.  IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants.

Authors:  H A Gans; Y Maldonado; L L Yasukawa; J Beeler; S Audet; M M Rinki; R DeHovitz; A M Arvin
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

3.  Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings.

Authors:  D E Craven; Z L Awdeh; L M Kunches; E J Yunis; J L Dienstag; B G Werner; B F Polk; D R Syndman; R Platt; C S Crumpacker
Journal:  Ann Intern Med       Date:  1986-09       Impact factor: 25.391

4.  Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants.

Authors:  H F Pabst; D W Spady; M M Carson; M P Krezolek; L Barreto; R C Wittes
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

5.  HLA and hepatitis B infection.

Authors:  A Almarri; J R Batchelor
Journal:  Lancet       Date:  1994-10-29       Impact factor: 79.321

6.  Use of synthetic peptides to identify measles nucleoprotein T-cell epitopes in vaccinated and naturally infected humans.

Authors:  C J Hickman; A S Khan; P A Rota; W J Bellini
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

7.  Th1 and Th2 cytokine responses after measles antigen stimulation in vitro in bone marrow transplant patients: response to measles vaccination.

Authors:  K Pauksen; J Sjölin; A Linde; G Alm; B Andersson; G Lönnerholm; P Ljungman
Journal:  Bone Marrow Transplant       Date:  1997-08       Impact factor: 5.483

8.  Several common HLA-DR types share largely overlapping peptide binding repertoires.

Authors:  S Southwood; J Sidney; A Kondo; M F del Guercio; E Appella; S Hoffman; R T Kubo; R W Chesnut; H M Grey; A Sette
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

9.  Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months.

Authors:  H A Gans; A M Arvin; J Galinus; L Logan; R DeHovitz; Y Maldonado
Journal:  JAMA       Date:  1998-08-12       Impact factor: 56.272

10.  Demonstration of virus-specific CD8+ memory T cells in measles-seropositive individuals by in vitro peptide stimulation.

Authors:  R Nanan; C Carstens; H W Kreth
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more
  3 in total

Review 1.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

2.  Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Nicholas M Pajewski; Conrad P Quinn; Richard A Kaslow; Robert M Jacobson; Gregory A Poland
Journal:  Infect Immun       Date:  2013-05-06       Impact factor: 3.441

3.  HLA-DR specific monoclonal antibodies block lymphoproliferative response to measles vaccine in vitro: a pilot study.

Authors:  David M Phelan; Gregory A Poland
Journal:  Vaccine       Date:  2012-08-31       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.